Archive for November, 2020
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are revolutionizing business practices within their respective markets. AZRX president and CEO James Sapirstein joins IBN’s Stuart Smith in the latest episode to discuss how AzurRx is working to redefine the standard of care for patients living with cystic fibrosis and chronic pancreatitis. “AzurRx Bio has been around for five years. … Our main product, MS1819, is being studied in chronic pancreatitis and in the GI effects of cystic fibrosis,” Sapirstein stated in the interview. “The market for this particular product, in chronic pancreatitis, competing against pancreatic enzyme replacement therapy (‘PERT’), is about $1 billion outside of the United States and several hundred million dollars inside the United States. The other market is cystic fibrosis. It’s over a $2 billion market worldwide for PERT.”
To view the full press release, visit: https://ibn.fm/uXWmJ
About AzurRx BioPharma Inc.
AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced the expansion of its WRAP Armor(TM) ballistic shield product line to include the Level IIIA Patrol Shield and the Molle Shield Cover in addition to the Level III Tactical Shield. “Our vision is to become a leader in providing public safety with advanced technology solutions to help protect law enforcement officers and the citizens they serve,” said Tom Smith, president and interim CEO at Wrap Technologies. “The introduction of our revolutionary BolaWrap(R) Remote Restraint device to law enforcement has enabled us to build a strong distribution network and customer base which we intend to leverage by continuing to innovate and provide public safety with needed solutions.”
To view the full press release, visit https://ibn.fm/G1Hdq
About Wrap Technologies Inc.
Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, LaGrange, St. Cloud and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Recent study reports that consumers are opting for single-serve beverages; bottled water outperforms carbonated beverages
- WTER’s flagship product — Alkaline88 — now available in easy-to-carry, two-liter single-serve bottles
- Company’s A88 flavor-infused water offering gaining significant market share, available in growing number of spaces
A growing number of consumers who drink and snack throughout the day are turning to single-serve, ready-to-drink beverages, often found most easily at c-stores, according to a recent Shop Association report (https://cnw.fm/82iZ2). Recognizing the market opportunity, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) recently launched a new 2-liter single-serve option to meet that increased customer demand (https://cnw.fm/y6hUs).
“Overall, the beverage industry is positioned to remain strong throughout the coming years with bottled water outperforming carbonated beverages,” reported the Shop Association study, which also noted that convenience is a key driver in the segment growth. “A recent global Packaging market research study from the Association for Packaging and Processing technologies found that customers tend to pick up grab-and-go foods for purchase as an impulse. Retailers and brands can capitalize on this impulse spending while finding ways to implement environmentally friendly messages and customizable elements into foodservice packaging. Grab-and-go programs for a product in a growing category is one way to increase incremental sales for both brands and retailers.”
Committed to meet the needs of consumers and retailers alike, WTER unveiled its flagship product — Alkaline88(R) — in new, easy-to-carry, two-liter bottles, available for purchase alone or in a six pack. “This unique six pack complements our existing line-up, especially our single-serve offerings, which continue to do well in the current environment,” said The Alkaline Water Company’s president and CEO Ricky Wright. “The two-liter format is extremely popular in the carbonated soft drinks segment but virtually nonexistent in the bottled water category.”
With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and perfectly represents the company’s trademarked Clean Beverage label.
In addition to Alkaline88 and in another show of its astute awareness of consumer demand and interest, The Alkaline Water Company also offers A88 Infused(TM). Available in seven all-natural flavors (with new flavors on the horizon), the flavor-infused water offering is gaining significant market share and is available in a growing number of spaces (https://cnw.fm/N4HlV).
“Demand for our single-serve offerings are at an all-time high, and we are rapidly growing shelf space for our A88 Infused flavored waters,” stated Wright. “Our channel partners are some of the leading players in the all-natural vertical and give us a reach into nearly 40,000 retailers nationwide. Our sales team is working closely with our partners to create ‘speed to market’ programs, including promotion and incentives to drive further momentum. We are doing a great job creating new leads, and currently, our flavors are carried by or have placement commitments from nearly 13,200 stores across the U.S. . . .Our A88 Infused brand is now available in some of the top supermarkets, retailers, and wholesalers, and we expect this trend to accelerate throughout our fiscal year.”
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. In addition to its A88 Infused(TM) water line, the company also recently launched A88CBD, a line of CBD-infused beverages. For its topical and ingestible offerings, A88 Infused products include both the company’s lab-tested, hemp extract salves, balms, lotions, essential oils, and bath salts, along with hemp extract powder packs, oil tinctures, capsules, and gummies.
For more information, visit the company’s websites at www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
In a bid to reduce carbon emissions and conserve the environment, several developed countries have pledged to phase out internal combustion engines for electric vehicles over the next decades. Powered by clean renewable energy and emitting zero emissions at the tailpipe, electric vehicles (“EVs”) are the perfect vehicle for a net-zero economy. Like the internet in the late ‘90s and early 2000s, EVs have completely disrupted the automotive industry, forcing players across the supply chain to either adapt with the times or be left behind.
For instance, the emergence of EVs has seen a rise in the use of “skateboard” platforms, especially by EV-only manufacturers such as Tesla. Designed exclusively for EVs, the skateboard platform uses a low, flat battery as the underbelly of the car, and it can be easily adapted to different car models. Compact motors for the wheels are placed at the four corners while the brakes, drive control, drive-by-wire accelerators and steering are mounted on the platform. The result is much less bulky than a traditional internal combustion engine and transmission blocks, and has fewer moving parts as well.
Electric chargers, specifically turbochargers, have seen immense demand as the transition to electric vehicles begins. One benefit of traditional vehicles is that they can be quickly refueled, compared to EVs, which can take hours to fill up with juice. Turbochargers can fill up an EV in minutes, increasing fuel efficiency and reducing carbon emissions. Hybrid vehicles are set to be the bridge between internal combustion engine vehicles, and EVs and turbochargers will allow for lower fuel consumption and reduced emission, especially as vehicle range increases.
Compared to EVs, internal combustion engine vehicles have plenty of moving parts, with the complex internal gearing being one of the most crucial. The gearing is used to optimize power and torque as the vehicle accelerates as well as to keep the engine running at peak efficiency within a wide range of engine speeds. A lot of energy is lost through all these processes in the form of heat, making ICE quite inefficient. EVs, on the other hand, have a relatively simple motor that consists of a central rotor connected to a single gear.
Drivetrain suppliers and original equipment manufacturers are currently using planetary gearing to develop multispeed transmission systems with greater range capabilities. Due to their light weight and compact designs, planetary gears increase battery use efficiency, leading to increased mileage. However, OEMs and drivetrain suppliers will have to find a way to cover up gear noise, vibrations and harshness as they can affect transmission performance.
Speaking of innovations in the electric vehicle industry, Net Element (NASDAQ: NETE), a global financial solutions company, will soon complete its merger with Mullen Technologies Inc., an EV company based in California. It will be interesting to see how the new entity performs in this rapidly evolving EV space.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
- China’s government has set out its next 5-year plan, highlighting promotion of electric vehicles as key tenet underpinning their environmental policies
- Net Element’s reverse merger with EV manufacturer Mullen Technologies is expected to close by 4Q2020, with Net Element expected to divest its legacy payments business following the deal
- Company aims to begin selling K50 Dragonfly sportscar by 2Q2021, recently began pre-sales for its wholly self-developed EV SUV, the Mullen MX-05
- US has followed in China’s footsteps, with Presidential candidate Joe Biden encouraging mass EV adoption as key policy initiative
Net Element (NASDAQ: NETE), a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through its binding letter of intent to merge with privately-held Mullen Technologies Inc., may have timed its move to perfection. The fifth plenum of the Chinese government concluded on October 29 following a four-day meeting. This year, the semi-annual gathering of China’s top leaders had a special task – finalizing the blueprint for the 14th Five-Year Plan, which will set out China’s economic policies for the period from 2021 – 2025 (https://ibn.fm/koCs5). One of the key undertakings adopted by the Chinese government during the plenum involved delineating a series of measures set to govern the development of the nation’s budding new energy vehicle (“NEV”) sector between 2021-2035, which aim to accelerate the country’s development into an automotive powerhouse.
The plan released by the State Council, China’s cabinet, listed a number of broad guidelines, namely – to improve the domestic Chinese auto sector’s capacity for technological innovation, build advanced industry ecosystems, and encourage further industrial integration and development. More specifically, the plan stated the Government’s ambitions of bringing the average power consumption of new, purely electric passenger cars down to 12 kWh/100 km while raising the market share of new NEVs within total automotive sales to 20% by 2025. By 2035, the Government aims to encourage the mass adoption of purely electric automobiles as a replacement to conventional internal combustion engine powered cars, while ensuring that all vehicles used in public transportation are completely electrified (https://ibn.fm/4QsI9).
Net Element and Mullen Technologies have revealed plans to begin their foray into the US electric vehicle market through their partnership with Chinese EV manufacturer, Qiantu Motors, with the aim of marketing and selling the latter company’s vehicles in the US. The joint-venture’s first product will be the K50 Dragonfly – an all-electric, two-seat, carbon-fiber-bodied sports car which can go from 0-100 km/hr in 4.6 seconds (faster than a Porsche Boxster) and which is set to begin deliveries from 2Q2021 onwards.
The company plans to follow on from their introductory model with the manufacture and sale of an entirely self-produced EV SUV, the Mullen MX-05, by the second quarter of 2022—with hopes of reaching a production threshold of 35,000 vehicles per annum by 2026. Mullen recently announced that the company has begun taking pre-orders for the MX-05 as of October 1, 2020 through its website as well as through any Mullen retail location in the U.S.
China’s NEV policies, while considerably more ambitious than those professed by the rest of the world, have resonated elsewhere around the globe. During his campaign, Democratic Presidential candidate Joe Biden set out four key targets driving his goals to encourage EV adoption – building 500,000 public EV charging stations by 2030, restoring the full EV tax credit, shifting government fleets to electric cars, and developing a new fuel economy target (https://ibn.fm/zqFBK).
Economies and governments the world over have positioned themselves for the mass promotion and adoption of electric vehicles as a key pillar underpinning their environmental goals. Through their upcoming tie-up (pending shareholder approval), as well as through their recent operational initiatives, Net Element and Mullen Technologies find themselves well positioned to respond to the rising tide of demand within the electric vehicle sector.
For more information, visit the company’s website at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
The national science agency for Australia, the Commonwealth Scientific and Industrial Research Organization (CSIRO) has entered into a collaboration with GTI, a U.S.-based firm that deploys various technology solutions to tackle environmental and energy challenges. The two bodies will be working together to create a carbon dioxide power plant that may help mining entities reach bigger targets in terms of renewable energy.
The organizations together released a press release that explained how the supercritical carbon dioxide power plants recirculated C02 at high temperature to generate electricity. This was in comparison with steam, which is widely used by most firms. Additionally, these supercritical plants can work using other heat sources and aren’t restricted to just one. Supercritical carbon dioxide is C02 in its fluid state, held above or at its critical pressure and temperature.
David Harris, the research director of energy technologies at CSIRO, said in the media statement that another benefit would be that the supercritical carbon dioxide was a working fluid of a higher density. This translated into more efficient and smaller power plants that do not rely on water to generate steam in order to function. Implementing the use of supercritical carbon dioxide on a wide scale could revolutionize how power was generated in Australia.
Additionally, supercritical carbon dioxide turbines provide a power cycle that’s not only high efficiency but also independent because it does not depend on steam. This makes the turbines an excellent solution for the generation of electricity in distant or secluded mining operations. This is mainly because it produces renewable energy that can be used to power various operations for extended lengths of time.
The main function of the Australian science agency in the project will be to better the comprehension of how low- or zero-emission technology solutions can be enabled by supercritical carbon dioxide power plants, particularly in places where firms rely on diesel as a power generator. Furthermore, the organization plans to study more about how concentrated solar thermal (CST) technologies can be utilized in supplying these power plants with renewable energy.
Apart from power generation, supercritical carbon dioxide can also be used to decaffeinate coffee by acting as a solvent to drain the caffeine from the coffee beans, which leaves behind the proteins and carbohydrate that give coffee its smell and flavor.
The process is also used as an environmentally friendly solvent in dry cleaning as it dissolves dirt in liquid form (recycled). This translates to no contribution to global warming.
Many mining companies are producers of minerals that are central to many industries. For example, Colorado-based Energy Fuels Inc. (TSX: EFR) (NYSE American: UUUU) is involved in mining vanadium and uranium, and the company has also started producing rare earth elements.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
Scientists have discovered that Netrin-G1, a protein that plays a role in neuron development in the brain, also has a hand in the growth and development of pancreatic cancer. The study results show that this particular protein protects pancreatic cancer cells from a person’s immune system while also providing important nutrients.
Pancreatic cancer is among the hardest cancers to treat as its tumors grow additional connective tissue in the pancreas. This helps the cancer grow while also providing it with a biochemical and physical protective barrier against an individual’s immune system as well as the drugs administered to fight the disease. Cancer-associated fibroblast, a cell that interacts with the disease’s cells to help it survive and grow, makes up this protective barrier.
Dr. Edna Cukierman, an associate professor at the Fox Chase Cancer Center in Philadelphia, explains that the researchers developed a system that they utilized in their study of cancer-associated fibroblast. Their study focused on how the cells behaved within the pancreas.
The key discovery showed that Netrin-G1 supports pancreatic cancer cell survival. The research was financed in part by the Worldwide Cancer Research and reported in Cancer Discovery. In addition to their findings, the researchers found that the antibody that counterbalanced the Neutrin-G1 protein impeded pancreatic cancer tumor development in mice. This shows that new treatments that combat pancreatic cancer can be developed.
Cukierman, who was also the lead of the study, stated that patients who had the Netrin-G1 protein expressed in the cancer-associated fibroblasts survived for a brief period of time. She says that, in the future, diagnosing patients might feature Netrin-G1 detection, adding that limiting the function of the protein would give researchers a basis for the development of better treatments for pancreatic cancer.
More than 10,000 individuals are diagnosed every year with pancreatic cancer in the UK. Sadly, more than 9,000 of these individuals succumb to the cancer. This specific type of cancer has very low survival rates, with only one in every 20 individuals surviving with the disease for a decade or more after they’ve been diagnosed. In the United Kingdom, every one in four individuals diagnosed with this particular cancer will live for more than one year.
Dr. Helen Rippon, CEO of Worldwide Cancer Research, stated that this new finding by Cukierman’s research team represented was progress, especially amid the coronavirus pandemic, adding that this showed researchers’ dedication to finding cures. The progress, Rippon says, is good news, especially to those who have lost a loved one to this deadly disease.
Many firms are engaged in working to provide remedies to different forms of hard-to-treat cancers. One such company is CNS Pharmaceuticals Inc. (NASDAQ: CNSP). This company’s main drug candidate is aimed at an aggressive type of brain cancer called glioblastoma multiforme.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. According to the update, the company, on Nov. 20, 2020, received notice from the USPTO that it will publish application 62/722,263 “Method of treating frozen shoulder using an il-33/TNF bispecific antibody.” The patent application is a continuation of US Patent No. 10,500,2730 and, once granted, it will be assigned patent number US-2020-0338193-A 1. 180 Life Sciences also received a notice of acceptance for its US patent, “Method of treating early stage Dupuytren’s Disease,” with the application number 16/089,234 filed September 27, 2018. Publication is expected to occur on Feb. 11, 2020. Additionally, the company received notification that the EU has granted its application number 15726740.2, filed on Aug. 29, 2016, which will be granted Dec. 9, 2020. “The issuance of these additional patent assets significantly strengthens the IP portfolio governing our lead program,” said Dr. James Woody, CEO of 180 Life Sciences. “We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies. Having these most recent patents awarded, particularly in the EU, is important as it provides validation in the 12 largest countries in the EU, including the UK, and provides the platform to be able to expand clinical trials, commercialization and partnering efforts throughout Europe.”
To view the full press release, visit: https://ibn.fm/mGAXk
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
A team of researchers from the University of Bath Addiction and Mental Health Group has discovered that street marijuana around the globe is substantially stronger now than it was 50 years ago. This, they say, increases the risk of harm. The team incorporated into its study a minimum of 80,000 marijuana samples that had been tested within the past five decades from street samples collected in New Zealand, Italy, Denmark, France, Netherlands, UK and the United States. The research was financed by the Society for the Study of Addiction with the study’s findings being reported in the “Addiction” journal.
The researchers explored how THC concentrations had changed in various types of marijuana as the years rolled by. In herbal marijuana, the team discovered that the concentration of THC registered a 14% jump in the years 1970 through 2017. This was largely because the growing popular share of more potent marijuana varieties such as sinsemilla, which was preferred to traditional herbal marijuana, had less THC and contained seeds.
The researchers found prior evidence indicating that using marijuana with higher THC levels frequently carries an increased risk of issues such as psychotic disorders and addiction. Dr. Tom Freeman, the study’s lead author, stated that as the strength of marijuana increased, the number of individuals who entered treatment for marijuana use problems also grew. More Europeans, he said, were now receiving treatment because of marijuana than cocaine or heroin.
The team discovered that the THC increase was especially high for cannabis resin, as THC concentrations spiked by 24% in the period 1975 through 2017. According to the study’s findings, cannabis resin, which is extracted from herbal marijuana, is generally stronger than herbal marijuana. The researchers also looked at CBD concentrations but found no evidence for changes in CBD in marijuana over time.
Sam Craft, the study’s coauthor, explained that hash or cannabis resin is commonly seen as safer than other marijuana types. However, their findings show that hash is now more potent than herbal marijuana. In the past, hash contained lower quantities of CBD and THC, and while cannabidiol’s concentration has not changed, the concentration of THC has grown considerably. This led the researchers to conclude that consuming the drug may be potentially more harmful today than decades ago.
Marijuana takes pole position among illicit drugs consumed across the globe and has been legalized recently in some states in the U.S. as well as in Uruguay and Canada. This study’s findings are particularly relevant as they shed light on the safety of marijuana as more call for it to be legalized in various nations around the world. The researchers assert that the rise in the strength of marijuana puts the spotlight on the need to execute broader strategies to reduce the drug’s harm, similar to the strategies used for liquor. These strategies include public guidelines on safer limits of consumption as well as standard units. This would help individuals limit their consumption and use marijuana more safely.
The cannabis sector is seeing major transformations orchestrated by many industry leaders. One of those industry leaders is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). The company specializes in using a proprietary electrolysis system to produce premium alkaline water, and WTER is also making edible and topical products infused with CBD.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
- Sustainable Green Team Ltd reported its financial results for 3 months ending Sept. 30, 2020
- Company reported 3Q20 revenues of $5.9 million, gross profit of $422 thousand, taking 9M20 revenues to $24.5 million and gross profit to $5.5 million
- SGTM also provided status update regarding its retailing tie-up with Circle K convenience stores, the geographical scope of which has now increased to include fourth region
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has recently published its financial results for the third quarter of 2020. The company has seen its fiscal revenues rise to total $24.5 million over the first nine months of 2020.
For the fiscal quarter ending September 30, 2020, SGTM reported $5,907,155 in revenue, $422,133 in gross profit and $36,140,923 in total assets, with a strong position of $5,936,798 in cash and liquid investments. In aggregate, that took the company’s total revenues for the first nine months of the year to $24,544,820 while recording $5,503,905 in gross profit (https://ibn.fm/aBJQN).
The company also seized the opportunity to expand on its numerous achievements over the course of past three months:
- Completion of company name and trading symbol change as of July 21, 2020
- SGTM awarded IPEMA certification to recycle tree and storm waste into public playground surfacing material on July 23, 2020, providing the company with access to a $4 billion market
- Completion of the dual line mulch bagger and fully automated electric grinding screening operation at Waste Management’s Apopka, Florida-based facility, increasing its mulch manufacturing capability by 4 million bags per year
- Addition of new grapple hauling trucks to the Company’s fleet, with each truck capable of hauling 1,250 loads per annum, equivalent to $400 thousand in gross revenue
- Obtaining a permit to accept debris and manufacture mulch at the company’s state-of-the-art, 100,000 square foot Jacksonville facility
“I am proud of our team and the progress we have made this year in achieving these key milestones,” commented Sustainable Green Team’s CEO and Director Tony Raynor in reference to the results. “We plan to proceed in a similar manner during the remaining quarter and end 2020 on a strong note. In keeping with that aim, we have already completed our two-year audit to commence our Form 10 process, which will enable us to begin 2021 as a fully reporting company and uplist accordingly.”
Separately, the company also took the opportunity to announce that it had signed a new mulch contract for 2021 with Circle K convenience stores, a subsidiary of Alimentation Couche-Tard, Inc (OTC: ANCUF). The original agreement with Circle K, signed in October 2020, was modified to add an additional region to the initial three regions in which SGTM’s mulch products would be marketed, thereby increasing the potential revenue potential from the tie-up (https://ibn.fm/ya2nW).
To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/vtjJ2.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
A new study by researchers from the University of Birmingham suggests that environmental cancer-causing agents may be used to help understand effects of exposure in addition to helping predict the individuals who may be more susceptible to developing cancer.
Every individual has been exposed to low levels of radiation or substances that promote cancer development, commonly known as carcinogens. Benzopyrene, which is a widely used chemical pollutant, is found in barbequed fish and meat, exhaust fumes and wood-burning stoves. The pollutant has BPDE, which is an active ingredient that forms DNA adducts. These are damaged DNA that promote mutations that give rise to cancer.
While researchers still don’t fully understood some pathways, models that demonstrate how BPDE leads to these mutations have been developed. Scientists believe that the mutation occurs through a process called translesion synthesis, which happened when cells replicate damaged DNA. However, research has also revealed that another process known as homologous recombination is also involved in the process. This process copies other undamaged parts of the genome.
The study researchers used BPDE to treat human cell lines before they used molecular biology methods such as microscopy to characterize the homologous recombination pathway in depth. The findings have shown that homologous recombination (HR) can be activated even when there isn’t any collapsed or stalled replication forks. Instead, researchers say that HR is activated in the DNA’s single-stranded gaps created by PrimPol’s re-priming activity. PrimPol is a protein encoded by the gene, PRIMPOL, which is found in humans.
The results also provide new insights that show that at bulky DNA adducts, HR products that have been traditionally linked to replication fork collapse and exchanges between sister chromatids are connected to post-replicative gap repair. Moreover, it was found that PrimPol produces these post-replicative gaps, which explains PrimPol’s function in DNA damage tolerance.
Eva Petermann, MD, the study’s corresponding author from the Institute of Cancer and Genomic Sciences, University of Birmingham, states that the study demonstrated how cells were affected when exposed to benzopyrene. This is important in helping researchers better understand cancer development in general and the environmental causes of cancer. Understanding this mechanism may help scientists better detect and predict the detrimental effects of pollution while also allowing them to better interpret cancer genomics.
As research progresses, Petermann explains that it will be important to look into the effect of such gene variants on homologous recombination at ssDNA gaps. She adds that a variant of the PRIMPOL gene may even have the potential to predict which individuals are more sensitive to carcinogen exposure.
Cancer takes a huge toll on society and many companies are doing their best to improve the delivery and effectiveness of cancer treatment. One such company is Predictive Oncology (NASDAQ: POAI). POAI specializes in improving patient treatment outcomes by combining the power of data and AI to personalize cancer treatment.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Net Element (NASDAQ: NETE) was featured in a recent report by Zacks Small-Cap Research that discussed the company’s third quarter showing sequential rebound as the merger proceeds with privately-held Mullen Technologies Inc. The report reads, “At its current enterprise value of $43.6 million, the stock is getting no premium for its pending merger and is valued only on its card processing business. Using the electric vehicle peer valuation of 10x EV/sales, and owning 15-21.7% of the post-merger company, the company could be worth $30.00 per share once the deal closes and twice that by 2023.”
To view the full press release, visit http://ibn.fm/dID9D
About Net Element Inc.
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement (the “Merger Agreement”) to merge with privately-held Mullen Technologies Inc. (“Mullen”), a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). That contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visit www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading producer of uranium in the United States, is poised with the unique abilities and resources to supply the nation with its growing demand for clean nuclear energy. This is good news for the company, as nuclear energy looks to have a bright future as the country moves toward cleaner, carbon-free power sources. A recent article discussing this reads, “Energy Fuels is America’s leading producer of uranium, which is the fuel for carbon-free electricity. Energy Fuels was also the largest domestic producer of vanadium in 2019. Vanadium is mainly used in steel and other high-strength alloys. But vanadium batteries, which can be used to store vast amounts of electricity generated from renewable sources, are also being commercialized around the world. The company is also entering the rare earth elements processing business. Rare earths are used in a whole host of advanced technologies, including in the clean energy sector.”
To view the full article, visit https://ibn.fm/3sw54
About Energy Fuels Inc
Energy Fuels is the number one U.S. producer of uranium. The company was also the top U.S. producer of vanadium in 2019 and is conducting pilot-scale testing to potentially begin producing a rare earth element (“REE”) concentrate at its White Mesa Mill. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, it is licensed to produce over 8 million pounds of U3O8 per year, and it has the ability to produce vanadium and a rare earth element concentrate. The Nichols Ranch ISR Project is fully licensed, constructed and on standby, and licensed to produce 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also fully licensed, constructed and on standby, and licensed to produce 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has the largest NI 43-101 compliant uranium resource portfolio in the U.S., among producers, and several uranium and vanadium mining projects on standby and in various stages of permitting and development. Energy Fuels’ corporate offices are in Lakewood, Colorado near Denver. For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in a recent Simply Wall St article. The piece, titled “Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?,” explores the rate of the company’s annual negative free cash flow (“cash burn”) and whether it should be concerning to shareholders. The article reads, “Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought AzurRx BioPharma’s cash burn reduction was relatively promising. Even though we don’t think it has a problem with its cash burn, the analysis we’ve done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future.”
To view the full press release, visit: https://ibn.fm/bL6D1
About AzurRx BioPharma Inc.
AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
GrowDiaries is an online community of cannabis growers that allows its members to ask questions, interact with other members and blog about their crops. In September, the company suffered a major security breach that left millions of users’ posts, passwords and other data exposed. The unprotected database was discovered by researcher Volodymyr “Bob” Diachenko on Oct. 10, 2020. Diachenko, who is known for pointing out unsecured databases, said the company was responsible for the vulnerability.
He reports on LinkedIn that two Kibana apps, which are usually used by IT and development staff to manage Elasticsearch databases, were left unsecured without a password since September 22. Through these two unsecured apps, attackers could access two sets of Elasticsearch databases. According to Diachenko, the databases consisted of around 1.4 million records containing IP addresses and email addresses and another 2 million records containing hashed account passwords and user posts.
The MD5 hashed format that the passwords were stored in is notoriously vulnerable, says Diachenko, and attackers could easily crack it and access the plain-text passwords, allowing them access to the users’ data. The exposed IP addresses spanned a wide range of provinces and countries, including a couple that still outlaw cannabis. After Diachenko reported the unsecured Kibana apps to GrowDiaries, the company secured its database but did not offer any further communication.
He states that since he probably wasn’t the only one looking for databases vulnerable to attackers, it is very likely that someone else was able to access and download user data from GrowDiaries’ Elasticssearch databases. Although the company has not replied to any inquiries on the matter, the website’s FAQ portion assures customers that their data is safe. “GrowDiaries is entirely safe and sound to use and retail outlet information on. We do not shop or share any particular information and facts. All meta-knowledge is erased.”
Diachenko advises GrowDiaries users to change their passwords across all platforms, not just on GrowDiaries, to avoid “stuffing” attacks. These kinds of attacks employ an automated bug that plugs in different combinations of stolen passwords and usernames in an attempt to break into other websites and apps.
Community members should also keep an eye out for phishing attacks where an individual is sent an email, text or instant message with a malicious link. Clicking on these links allows attackers to install malware onto your system, freeze it as part of a ransomware attack orsteal funds and sensitive information.
An entity that you should watch in the cannabis industry is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). This company not only makes premium alkaline water but also has a line of CBD-infused topical as well as ingestible products.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that it has added a new foodservice broker, IBA Foodservice. According to the update, the new partner will present the A88 family of beverage products to the entire hospitality channel. “We now have two formidable partnerships in DOT Foods and IBA Foodservice to help us gain share in the hospitality and foodservice channel,” said Ricky Wright, president and CEO of The Alkaline Water Company. “IBA is a highly respected professional foodservice sales and marketing organization comprised of thirty successful agencies. With deep, long-term market-by-market relationships, the IBA has stellar local expertise in a well-connected, collaborative and nationally respected alliance of independent brokers. Between our two partners, we expect DOT Foods to provide access to large national accounts, and IBA to help us penetrate the large regional accounts across the entire hospitality and foodservice ecosystem. These partners give us the scale and scope to drive our growing lifestyle brands in the sizeable on-premise market estimated at over $14 billion by Beverage Marketing Corporation. This segment includes restaurants, hotels, airports, stadiums, hospitals, schools, colleges/universities, parks, golf courses, health and fitness clubs, coffee shops, etc. We expect our single-serves, including A88 Infused flavors, eco-friendly aluminum bottles, and A88CBD infused lemon-lime water to do exceptionally well in the channel.”
To view the full press release, visit: https://cnw.fm/PQIwz
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
- Sales of CBD products through convenience, gas stores grew by 2,276% in 2019.
- CBD drinks, valued at $52 million in c-store sales in 2019, are highly popular among new consumers.
- WTER offers A88CBD(TM) product line including beverages and lab-tested, hemp extract gummies, capsules, salves, balms, lotions and more.
As the use of cannabidiol (“CBD”) becomes more mainstream, convenience stores are in an ideal position to benefit from the product’s rapid growth, according to a recent CBD Retail Trends article (https://cnw.fm/j0fIO). That’s good news for The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), a company with a robust CBD-infused beverage line and a growing distribution network encompassing convenience stores around the country.
“While few consumers had heard of CBD prior to 2018, the signing of the farm bill in December 2018 — which removed hemp from the legal definition of marijuana and the Schedule 1 Controlled Substances list — helped usher in exponential growth through extensive media coverage, expanded product availability including in drug stores and pharmacies, and widespread word-of-mouth through social media,” reported the CBD Retail Trends article. “Sales of CBD products through convenience and gas stores grew by 2,276% in 2019 to reach $122 million.
“CBD drinks, valued at $52 million in c-store sales in 2019, are highly popular among new consumers and skew younger, with millennials as the largest consumer group,” the article continued. “Demand for CBD-infused drinks remains high despite the Food and Drug Administration (“FDA”) stating that CBD cannot be sold as a dietary supplement or used as a food additive.”
Those numbers may be only the tip of the iceberg for CBD potential in the c-store channel. WTER’s high-quality line of A88CBD(TM) represents the company’s commitment to offer industry-leading, hemp-derived CBD products that meet consumers needs and support their daily wellness routines. The A88CBD product line features an exclusive line of CBD-infused beverages as well as an expansive line of lab-tested full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with hemp extract powder packs, oil tinctures, capsules, and gummies.
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. Additionally, in 2020, the company launched its A88CBD Infused line of ingestible and topical products, including its CBD water.
To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
- EV battery prices becoming increasingly economical, dropping 87% in less than decade with additional 30% drop predicted by 2023
- NETE plans to divest payments processing model to enter EV industry through merger with privately-held Mullen Technologies Inc.
- Battery-focused subsidiary Mullen Energy part of US expansion, thousands of jobs expected to be created
- Pre-orders for MX-05 SUV commenced, production expected to start in 2021
The average real price of electric vehicle (“EV”) batteries has dropped 87% in less than a decade (https://ibn.fm/GRCa9) and is projected to drop even further due to technological innovations destined to make EVs a viable alternative to gas-powered vehicles. Net Element (NASDAQ: NETE), through its pending merger with Mullen Technologies, will be well-positioned to benefit from this trend through Mullen Energy, a Mullen subsidiary focused exclusively on advancing battery technology.
While the current decrease in battery prices is impressive, analysts predict an even further 30% drop over the next three years, reaching a point where EVs will start to reach price parity with internal combustion engine vehicles. A combination of factors concerning battery technology is suggested to contribute to this shift that include cell design, production innovation, changes in the anode materials, changes in the cathode materials, and innovations that will change how the battery is integrated into the car.
Mullen Technologies is already well on its way to making substantial progress on battery technology through subsidiary Mullen Energy. Along with Mullen Auto Sales, Mullen Finance Corp. and a digital marketplace called CarHub, Mullen is well-positioned to expand its footprint in the United States with plans to expand and construct new production facilities that will bring thousands of jobs to the country.
Pre-orders for the five-passenger MX-05 SUV have already started, and manufacturing is expected to commence in the third quarter of 2021 with delivery dates set for the second quarter of 2022. Along with the MX-05, Mullen is planning to build and lease 1.3 million square feet of assembly and manufacturing space in Washington to produce the Dragonfly K50 electric sports car.
The time has never been better to expand into the EV industry. Research by BloombergNEF has suggested that nearly half of all passenger car sales in China will be electric by 2025 (https://ibn.fm/6ZwNQ). Along with the falling prices of batteries, EV mandates across the world paired with changes in fuel regulations are destined to contribute to EV dominance, projected to take over the municipal bus market by 81%, light commercial vehicle sales at 56%, and the medium commercial market at 31%.
A global financial technology and value-added solutions group, NETE has traditionally supported electronic payments acceptance in an omni-channel environment that included point-of-sale, e-commerce and mobile devices. Once ranked as one of the fastest-growing companies in North America by Deloitte, NETE plans to divest its payments-as-a-service business model to enter the electric vehicle industry through a reverse-merger with California-based Mullen Technologies.
For more information, visit the company’s website at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
The race towards fully electrifying our roads is on, and the UK has announced one of the most ambitious plans for replacing conventional vehicles with electric vehicles (“EVs”). The UK government has announced that it plans to bring forward its ban on the sale of new internal combustion engine vehicles from 2040 to 2030 as it looks toward becoming a net-zero economy. As such, numerous regions have been vying for the honor of hosting the UK’s first gigafactory, which will manufacturer electric vehicle batteries.
First popularized by American EV maker Tesla, a gigafactory is a large manufacturing facility that can produce up to 15GWh per year. Such factories can ease the transition from internal combustion-engined vehicles to electric vehicles by producing battery cells and packs to power the EVs. With the UK government pledging to contribute as much as £1bn ($1.33bn) to an automotive transformation fund, the country may have enough gigafactories to support full EV adoption.
However, despite hastening its plans to ban the sale of new internal engine vehicles and pledging funds to help the transition, the UK government hasn’t said how these funds will be used. According to an inside source, two serious investors are in discussions with the authorities, and one potential plan would involve a joint venture between European and British companies. With major automakers in the UK such as BMW, Nissan, and Jaguar Land Rover being pressured to switch from internal combustion engines to electric powertrains, the auto industry is impatiently waiting for the government to make a commitment.
According to a business department spokesman, the government recognizes the need for a “robust battery supply chain” if the country is to achieve full EV adoption within the given timeline. As such, securing investment for gigafactories is a top priority. Julian Hetherington, director of automotive transformation at the Advanced Propulsion Center (“APC”), says demand for EV batteries will go up as more automakers go electric. That upward movement will help secure investments for gigafactories. Predictions put the UK industry’s energy needs at 60 gigawatt-hours a year, meaning the country will need four gigafactories to meet the demand.
As the 2030 ban on the sale of fossil fuel vehicles draws closer and automakers such as Bentley unveil plans to electrify their entire line-up, the need for gigafactories will grow even greater. A single gigafactory can avail thousands of jobs — Tesla’s Nevada facility has around 7,000 employees — and plenty of regions want in on that action. South Wales, the West Midlands and the northeast of England have all thrown their hats into the ring. On top of creating plenty of jobs, a gigafactory would greatly boost the UK’s struggling automotive sector.
The EV sector across the globe is seeing a flurry of activity as many companies hope to capitalize on the wave bringing electric vehicles to the mainstream. One of the noteworthy entities you should follow is Net Element (NASDAQ: NETE). The global financial solutions firm recently announced a merger with a California-based EV maker called Mullen Technologies Inc.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (“DTS”). According to the update, the results showed a marked reduction in the percentage of high blood glucose readings and in the average blood glucose readings in adults over the age of 65 years using Dario’s digital therapeutics platform (“Dario DTx”). “We believe that Dario’s DTx platform plays a role in driving behavioral modification and enhances adherence to diabetes and other chronic condition management in older adults,” said Yifat Hershcovitz, Ph.D., scientific and clinical director at DarioHealth. “The results show that the platform can significantly reduce the percentage of high blood glucose ratios and may facilitate significant improvement in clinical outcomes, leading to better health outcomes for older individuals with diabetes.”
To view the full press release, visit http://ibn.fm/cS0uf
About DarioHealth Corp.
DarioHealth is a leading, global digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its consumer-centric MyDario(TM) mobile app is loved by tens of thousands of members worldwide. DarioHealth is rapidly moving into new geographic markets to meet the needs of additional chronic conditions, using a performance-based approach to improve members’ management of chronic disease. To learn more about the company and its digital health solutions, visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
According to new research that was reported in “Circulation,” the American Heart Association journal, adults who had healthy sleeping patterns had a lower risk of heart failure. This was in comparison to grown-ups who had unhealthy sleep patterns.
Healthy sleeping patterns are characterized by waking up in the morning, sleeping seven to eight hours every day and having no excessive daytime sleepiness, snoring or frequent insomnia. Emerging evidence shows that sleep problems may have a hand in heart failure development. Heart failure affects over 26 million individuals globally.
The observational study looked into the relationship between heart failure and healthy sleep patterns. It included the data on 408,802 Biobank participants from the UK, who were aged between 37 and 73 at the time of recruitment, which was between 2006 and 2010. The prevalence of heart failure was collected until April 1, 2019. Researchers documented 5,221 heart failure cases during a follow up of 10 years.
Researchers examined overall sleep patterns and sleep quality. Measures of sleep quality included snoring, insomnia, sleep duration and other features related to sleep, such as whether a participant had any daytime sleepiness or if they were a night owl or an early bird. The professor of epidemiology and the corresponding author of the study, Lu Qi, stated that the team had developed a healthy sleep score based off of the scoring of these five sleep behaviors.
Qi, who is also the director at Tulane University’s Obesity Research Center in New Orleans, added that the study results emphasized the importance of improving overall sleep patterns as a way to prevent heart failure.
In the study, sleep duration was defined in three categories: 9 hours or more daily (prolonged), seven to eight hours daily(recommended) and less than seven hours daily (short). After the researchers adjusted for genetic variations, medication use, hypertension, diabetes and other covariates, they discovered that the participants with very healthy sleep patterns had a 42% lower risk of heart failure as compared to those who had unhealthy sleep patterns.
They also discovered that the risk of heart failure was independently linked and was 34% lesser in participants who reported no daytime sleepiness, 17% lesser in participants who didn’t have frequent insomnia, 12% lesser in individuals who slept for the recommended time frame and 8% lesser in participants who were early risers.
Sleep behaviors by the participants were self-reported with researchers noting that other unknown or unmeasured adjustments may have influenced the study’s findings.
Lots of companies are investing heavily in helping people to adjust their behaviors so that serious or chronic health conditions can be managed effectively. One of those firms is DarioHealth Corp. (NASDAQ: DRIO). The company provides smartphone-based, chronic, disease-management software to make it possible for better disease management.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, will be joint sponsoring the 2020 Society of NeuroOncology (“SNO”) Virtual Meeting. CNS will be sharing sponsorship with WPD Pharmaceuticals. The virtual event is slated for Nov. 19–21, 2020. The joint sponsorship includes a booth in the virtual exhibit hall and is categorized as a Supporter level. In addition, one of the panel discussions will feature a member of CNS’s Science Advisory Board; Dr. Patrick Wen will be part of the panel discussing clinical trials. That particular event is scheduled for Friday, Nov. 20. Wen will also participate in online poster presentations.
To view the full press release, visit http://ibn.fm/e8g03
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease
- The company plans a complex, multi-armed Phase 2 trial of its candidate Berubicin in hopes that the drug candidate may ultimately gain an expedited pathway to approval and registration from the FDA
- The trial for combatting Glioblastoma Multiforme is expected to begin next year, and on Nov. 12 the company’s officers launched a webinar to provide information on how the trial will be designed
- CNS Pharmaceuticals is also preparing, in partnership with its sub-licensee WPD Pharmaceuticals, for two additional trials of Berubicin to be conducted in Poland including the first-ever Phase 1 pediatric trial as well as a parallel Phase 2 trial in adults
A biopharmaceutical company working to find a better way of treating an aggressive form of brain tumor, Glioblastoma Multiforme (“GBM”), which is currently regarded as incurable and ultimately fatal, announced recently that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review. It includes a novel clinical trial design it hopes will lead to a breakthrough, and on Nov. 12 company officers discussed the design for the upcoming Phase 2 U.S. trial in a webinar open to the public (https://ibn.fm/bV2e2).
“I would like to remind everyone that this upcoming Phase 2 trial will build on the success of the Phase 1 trial of Berubicin in which the clinical benefit response was 44 percent, including one patient … who had a durable complete response and is still alive and cancer-free today, 14 years after treatment with Berubicin, and another two patients with partial responses, who had reductions of greater than 25 percent in the size of their tumors,” CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco told the webinar audience.
CNS Pharmaceuticals’ lead drug candidate in treating GBM, Berubicin, is an anthracycline.
“Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers, including breast, ovarian, lung, lymphoma and leukemia, and other malignancies as well. However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain,” Climaco said.
“Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies,” he said.
CMO Dr. Sandra Silberman explained that the Phase 2 trial will allow a real-time comparison between Berubicin patients and patients receiving the normal standard of care, using “interim analyses that could impact and in fact reduce the numbers of patients required to establish the effectiveness of Berubicin.”
Under the parameters of the trial, 243 patients will participate, 162 of them receiving Berubicin and the other 81 receiving the chemotherapy drug lomustine. About 60 study centers will be used in North America, Europe and the Asia-Pacific region. Once 50 percent of the patients have been in the study for six months, the interim analysis will begin.
“We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” Silberman said.
The study will also be designed to preserve patient safety even with the continuation of the COVID-19 pandemic and GBM patients who don’t ultimately qualify for the study will be allowed other avenues to try Berubicin under U.S. “right to try” laws.
“We now have a drug supply manufactured and will do our best to get these patients that could benefit from Berubicin and have failed standard therapies (to where they) can be part of these parallel studies for which we will continue to accrue safety and efficacy information,” Silberman said.
Additional information about such opportunities will be posted on the company’s website.
Climaco said the complex trial design is not only the most potentially beneficial for studying Berubicin’s effects, but ultimately the most cost-effective design for the company’s shareholders as well because the Phase I trial not only showed the drug’s potential for safe use, but efficacy also.
“Rather than conduct a single-arm trial of Berubicin that would likely simply show us more interesting positive data, we chose to effectively allow our Phase 2 trial to incorporate an arm receiving standard of care such that any significant impact of Berubicin could be better analyzed,” he said.
Because the trial is expected to eventually cost $30 million to $35 million, Climaco said the company is taking a phased fund-raising approach over the next two to two and a half years, progressing from one success to the next rather than trying to raise all of the capital at once. Sound results from the Phase 2 trial could potentially sway the FDA to grant Berubicin an expedited pathway to approval, which would save time in the long run.
“Which is of course the valuable important commodity here,” he said.
CNS Pharmaceuticals is also preparing, in partnership with its sub-licensee WPD Pharmaceuticals, for two additional trials of Berubicin to be conducted in Poland. The first is a first-ever Phase 1 pediatric trial. The secondi s a parallel Phase 2 trial in adults that will be used as additional data to supplement and strengthen the data submitted to the FDA from the primary trial conducted by CNS Pharmaceuticals.
CNS Pharmaceuticals is also developing a drug candidate known as WP1244 with a DNA-binding agent that preclinical studies have shown to be 500 times more potent than chemotherapy drug daunorubicin in stopping tumor cell expansion. This drug is undergoing additional pre-clinical studies in preparation for a potential future Phase 1 clinical trial.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced that its controlling subsidiary Xunpusen Technology Co. Ltd. has signed an agreement with China Mobile Communications Group Guangdong Co. Ltd. for a series of Telecom value-added service and Internet Data Center (“IDC”) contracts. “Blue Hat’s cooperation with China Mobile has broadened new channels for our products, as we immediately began seeing greater traffic for our mobile products. In addition, we were able to provide a more flexible and efficient service and marketing model, and thus improved the interaction and service with end customers,” said Xiaodong Chen, CEO of Blue Hat. “We believe that this business cooperation may generate a stable and sustainable profit and further the expansion and brand recognition of our products.”
To view the full press release, visit http://ibn.fm/SuPrj
About Blue Hat
Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
According to ongoing research that was presented during a recent virtual meeting at the American Heart Association Scientific Session, it was discovered that limiting meals to early in the day didn’t affect the weight of overweight adults who have diabetes or prediabetes.
Associate professor of epidemiology, nursing and medicine at Johns Hopkins, Nisa M. Maruthur, the study’s author, stated that researchers had questioned the possibility of whether the time that an individual ate during the day affected how their body stored and used energy. Prior studies had not controlled the number of calories people consumed. It had therefore not been clear whether individuals who ate earlier in the day ate fewer calories. To remedy this, their study changed the time during the day when an individual ate.
During their three-month study, Maruthur and her colleagues observed 41 adults who were overweight. A majority of the participants were black women with an average age of 59 years who had diabetes or prediabetes. They made up 90% of the participants in the study. During the study, twenty participants ate in a 12-hour window at their usual eating times, ingesting half of their daily calories after 5 p.m. for the entire duration of the study. The remaining 21 participants followed an eating pattern that was time restricted.
This limited their eating to specific hours of the day. They consumed 80% of their daily calories before 1 p.m. with all 41 participants eating the same healthy, preprepared meals that were provided for them in the study. At the beginning of the study, the blood pressure and weight for each participant was measured. This was then measured four weeks and eight weeks after the study commenced, as well as when the study ended.
The researchers’ analysis discovered that individuals in both groups had decreased blood pressure and had lost weight, regardless of what they consumed. Maruthur explained that initially, they thought the group that had a time-restricted eating pattern would lose more weight. However, they noted no differences in weight loss in either groups.
Currently, the researchers are gathering more detailed information on blood pressure documented over a 24-hour period. They will then compile this information with the findings of a study that centered on the effects of time-restricted eating on insulin, blood sugar and other hormones. Maruthur added that, when combined, the findings from both studies would help the researchers better understand the impact time-restricted feeding had on cardio-metabolic health.
Many companies are out there contributing to improving human health in different ways. One of those dedicated companies that you should pay attention to is AzurRx BioPharma Inc. (NASDAQ: AZRX). AzurRx is focused on developing novel treatments for diseases that affect the gastrointestinal tract.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health care platform, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational. According to the update, the investor conference is scheduled to take place virtually on Dec. 1, 2020. Trxade Group CEO Suren Ajjarapu will, beginning at 3:40 p.m. Eastern Time on the day of the conference, host a virtual presentation to investors followed by a guided question and answer session. Interested parties may visit https://ibn.fm/OWrjU to register for the webinar and access a live audio webcast and a 90-day archived replay of the conference presentation.
To view the full press release, visit http://ibn.fm/P7xeO
About Trxade Group Inc.
Headquartered in Tampa, Florida, Trxade Group is an integrated drug procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms: (1) the Trxade B2B trading platform with around 11,800 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; and (3) the Bonum Health platform offering affordable telehealth services. For additional information, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “F2Q revenue was negatively impacted by retailers working through excess water inventory purchased during the pandemic period. However, WTER continues to build market share and retailer buying trends have now normalized. While we lower FY22 sales 7% to $63.1mm to be conservative, we note 1) WTER trades for 1.6x EV/Revenue versus larger, yet slower growth peers at ~6.0x; and 2) its penetration into the hospitality and CBD market offers significant potential upside to our/consensus FY22 estimates. Maintain Buy.”
To request access to the full report, visit http://ibn.fm/D1r9T
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Globally, some of the most popular breakfast food includes eggs, be it boiled, poached or scrambled. However, new research shows that excessive consumption of eggs may increase your risk of diabetes.
The longitudinal study, which was conducted by researchers from the University of South Australia in collaboration with Qatar University and China Medical University, was carried out between 1991 and 2009. This was the first study to evaluate the consumption of eggs in a large number of Chinese adults.
The study discovered that individuals who consumed one or more eggs on a regular basis, which is equivalent to 50 grams, increased their risk of diabetes by 60%. Currently, diabetes prevalence in China is above 11%, which is more than the global average of 8.5%. Diabetes has developed into a serious public health concern in the country.
Diabetes has not only affected the health but also the economy of some countries, accounting for 10% of the world health expenditure. In China, costs related to diabetes have surpassed $109 billion.
Dr. Ming Li, an epidemiologist and public health expert, states that the increase in diabetes cases is a growing concern, especially in China where changes to the conventional Chinese diet are affecting health. Li adds that diet is a factor that contributes to the onset of type 2 diabetes. Therefore, understanding the various dietary factors that may affect the increasing prevalence of the disease is crucial.
In the past few decades, China has gone through a nutritional transition that’s seen a lot of individuals move from a more conventional diet consisting of vegetables and grains to a more processed diet comprising of energy-dense food, snacks and meat. In the same period of time, the consumption of eggs has also been increasing steadily, with the number of people eating eggs almost doubling in China, from 1991 to 2009.
The study’s aim was to evaluate the people’s egg consumption on a long-term basis as well as their risk of developing diabetes. This was determined by fasting blood glucose. The study discovered that consuming more than 38 grams of eggs per day increased the diabetes risk in Chinese adults by nearly 25%.
Moreover, as stated above, grown-ups who ate more than 50 grams of eggs every day (one egg), grew their risk of getting diabetes by 60%. The impact was found to be more evident in women. Li noted that more research is required to look into the causal relationships.
A player in the biomedical field that you need to pay attention to is Processa Pharmaceuticals Inc. (NASDAQ: PCSA). This company specializes in advancing drug candidates that are at the stage of undergoing clinical trials.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of pressure-based instruments, consumables and platform solutions to the worldwide life sciences and other industries, on Tuesday released financial results for the third quarter ended September 30, 2020. In addition, the company provided a business update and offered limited guidance for fiscal year 2021. “We are delighted with the results of the third quarter 2020, particularly in the measurable progress made in three important areas: (i) key operational and technical projects . . . ; (ii) revenue increases in our products and services offerings; and (iii) important restructuring improvements in the reduction of onerous, variable-rate convertible debt,” said Richard T. Schumacher, president and CEO of Pressure BioSciences. “As previously reported, the company’s first and second quarter 2020 results were substantially impacted by business interruptions and/or distractions for PBI clients and prospects. However, third quarter 2020 results demonstrated a dramatic recovery, with Q3 total revenue exceeding the revenue of Q1 and Q2 2020 combined and topping all previous quarterly revenue results since Q4 2018. Similarly, instrument sales in Q3 2020 exceeded instrument sales in Q1 and Q2 2020 combined, and contracted services revenue for our Ultra Shear Technology(TM) (“UST(TM)”) nanoemulsions and BaroFold(TM) biopharmaceutical protein refolding and recovery platforms in Q3 2020 also exceeded revenue for the same services in Q1 and Q2 2020 combined.”
To view the full press release, visit https://ibn.fm/dJXa6
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Pressure BioSciences’ primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
The lockdown resulting from the ongoing pandemic has affected many sectors globally, with the natural resource sectors in various countries experiencing major losses. In Mexico, September figures show signs of improvement as the sector stabilized. According to Inegi, a statistics agency, activity in Mexico’s mining sector increased by 1.8%,in comparison with August 2019’s activity.
Earlier in the year when mines were suspended in April and May to comply with restrictions brought about by the pandemic, contractions of 25.1% were recorded in April and 17.8% in May. June saw operations increasing, as mining was declared to be an essential industry. Growth in the mining industry in June recorded an increase of 2.2%, with July showing more promise at 6.3% growth. Mining activity decreased by 7.7% in this year’s January–September period when compared to the same period in 2019.
However, August recorded a 1.1% decrease, right after the sector began to rebound and an overall decline in mine production of 3.7%, with the production of silver and gold decreasing when compared to August 2019 production. This is despite the increase in output of key industrial metals such as lead, zinc and copper.
Mexico is a top-10 miner of zinc, lead, copper and gold, and is the largest producer of silver globally. The country’s production of fluorspar increased to 96,613 tons, which is equivalent to 14.9%. The production of copper, lead and zinc increased by 0.9%, 15.8% and 28.2%, which equates to production of 40,340 tons, 13, 979 tons and 26,818 tons respectively.
On the other hand, silver and gold, as mentioned above, declined by 4.5% and 8.9%, which led to the production of 314, 825 kg of silver and 6,036 kg of gold. Gypsum, sulfur and noncoking coal also decreased by 6.5%, 7.2% and 7.8% respectively, leading to a decreased production of 422,912 tons, 31,589 tons and 498,075 tons.
The growth registered in production in the months of June and July was mainly because of weak production in both months in 2019, when output decreased by 9.6% and 6.5%. Mining companies have recorded production rebounds in this year’s third quarter in comparison to the production levels in the second quarter. However, pandemic-related protocols, which may require the number of workers on a site to be reduced, may affect mining operations for a period of time.
A notable mining company that you should watch is Energy Fuels Inc. (TSX: EFR) (NYSE American: UUUU). This Colorado-based firm specializes in producing vanadium and uranium, and the company also has interests in other verticals, such as rare earths and land clean-up.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
